Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

24.19 +0.17 (+0.71%)

Streaming Delayed Price Updated: 1:52 PM EST, Nov 17, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	564,245
Open	23.65
Bid (Size)	24.14 (100)
Ask (Size)	24.20 (100)
Prev. Close	24.02
Today's Range	23.34 - 24.50
52wk Range	13.40 - 26.65
Shares Outstanding	162,625,379
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Beyond The Numbers: 6 Analysts Discuss ACADIA Pharmaceuticals Stock ↗

November 06, 2025

Via Benzinga

Acadia (ACAD) Q3 2025 Earnings Call Transcript ↗

November 05, 2025

Acadia (ACAD) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Performance

YTD	+29.6%	+29.6%
1 Month	+15.8%	+15.8%
3 Month	-3.5%	-3.5%
6 Month	+10.0%	+10.0%
1 Year	+42.0%	+42.0%

More News

Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview

November 05, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

Earnings Scheduled For November 5, 2025 ↗

November 05, 2025

Via Benzinga

ACADIA Pharmaceuticals's Earnings: A Preview ↗

November 04, 2025

Via Benzinga

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Presents a Compelling Growth and Breakout Profile ↗

November 04, 2025

Via Chartmill

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

October 28, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

Halper Sadeh LLC Encourages Acadia Pharmaceuticals Inc. Shareholders to Contact the Firm to Discuss Their Rights

October 22, 2025

From Halper Sadeh LLC

Via Business Wire

This ACADIA Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗

October 21, 2025

Via Benzinga

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Fits the 'Affordable Growth' Investment Framework ↗

October 21, 2025

Via Chartmill

Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025

October 15, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Shows Strong Growth and Positive Technical Setup ↗

October 09, 2025

Via Chartmill

Leap Therapeutics (LPTX) Plummets Over 20% Amidst Profit-Taking and Volatility Ahead of Key Clinical Data

October 03, 2025

Via MarketMinute

Acadia Pharmaceuticals Presents Clinical Data from Across Multiple Therapeutic Programs at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®

October 02, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

Beyond The Numbers: 11 Analysts Discuss ACADIA Pharmaceuticals Stock ↗

September 29, 2025

Via Benzinga

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Presents an Affordable Growth Opportunity ↗

September 29, 2025

Via Chartmill

Acadia Pharma Faces Trial Setback As Prader-Willi Syndrome Trial Falls Short ↗

September 24, 2025

Via Benzinga

Acadia Pharma Tumbles On Failed Appetite Suppressant; Soleno Surges ↗

September 24, 2025

Via Investor's Business Daily

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

September 24, 2025

Via Benzinga

Acadia Pharmaceuticals’ Investigational Drug For Rare Genetic Disorder Fails In Late-Stage Study ↗

September 24, 2025

Via Stocktwits

Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint

September 24, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Shows Strong Technical Setup for Potential Breakout ↗

September 19, 2025

Via Chartmill

Real World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Developmental Medicine and Child Neurology

September 12, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

Assessing ACADIA Pharmaceuticals: Insights From 12 Financial Analysts ↗

September 09, 2025

Via Benzinga

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 08, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

Frequently Asked Questions

Is ACADIA Pharmaceuticals Inc. - Common Stock publicly traded?

Yes, ACADIA Pharmaceuticals Inc. - Common Stock is publicly traded.

What exchange does ACADIA Pharmaceuticals Inc. - Common Stock trade on?

ACADIA Pharmaceuticals Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for ACADIA Pharmaceuticals Inc. - Common Stock?

The ticker symbol for ACADIA Pharmaceuticals Inc. - Common Stock is ACAD on the Nasdaq Stock Market

What is the current price of ACADIA Pharmaceuticals Inc. - Common Stock?

The current price of ACADIA Pharmaceuticals Inc. - Common Stock is 24.19

When was ACADIA Pharmaceuticals Inc. - Common Stock last traded?

The last trade of ACADIA Pharmaceuticals Inc. - Common Stock was at 11/17/25 01:52 PM ET

What is the market capitalization of ACADIA Pharmaceuticals Inc. - Common Stock?

The market capitalization of ACADIA Pharmaceuticals Inc. - Common Stock is 3.93B

How many shares of ACADIA Pharmaceuticals Inc. - Common Stock are outstanding?

ACADIA Pharmaceuticals Inc. - Common Stock has 4B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.